Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 7th World Congress on Control and Prevention of HIV/AIDS, STDs & STIs
Venue: Hotel Barceló Valencia- Valencia, Spain .

Day 1 :

Keynote Forum

Reza Nassiri

Michigan State University, USA

Keynote: Antimicrobial resistance in HIV patients
Conference Series STD-HIV AIDS 2019 International Conference Keynote Speaker Reza Nassiri photo

Reza Nassiri is a former Associate Dean of Global Health at the Michigan State University. He also served as the MSU Director of Institute of International Health. He is currently Professor of Clinical Pharmacology and Toxicology, Professor of Family and Community Medicine and Lecturer in Global Health, Infectious Diseases and Tropical Medicine. He currently works on international public health issues relating to chronic diseases and has expertise in global health. He has made contributions in various fi elds of medical sciences including clinical investigation and health education. He had served as an Editorial Board Member for the journal of HIV and AIDS Review. He is currently on Editorial Board Member for AIDS Patient Care and STDs, J of AIDS Clin Res., and Int. J. of Global Health. He is the Founder of Michigan State University Osteopathic and Primary Health Clinic in Merida, Yucatan, Mexico. His research interests include Clinical Pharmacology of HIV/AIDS, Viral Pathogenesis, Antibiotic Resistance, Prevention and Control of Infectious Diseases, Tropical Medicine, Global health and Community-based Public Health Interventions.


According to the WHO, there is an estimated 36.7 million people living with the human immunodeficiency virus (HIV). While antiretroviral drug resistance is a common genetic trait of HIV which oft en results in treatment failure, there is a paucity of information of the development of antibiotic resistance in HIV patients. Along with the CD4 cells, HIV targets other cells of the immune system resulting in immunodeficiency, and thus, such a weakened immune response increases opportunity for bacterial, fungal and other viral infections. Pathogens such as Streptococcus pneumoniae, Salmonella, Hemophilus, Staph aureus, E. coli, Klebsiella and Pseudomonas are the risk pathogens that are encountered in HIV patients. However, the frequency of bacterial infections which are especially common in the lower CD4 counts, necessitate more administration of antibiotics either for prophylaxis or treatment purposes. One of the most clinically challenging threats is the production of extended-spectrum β-lactamases (ESBLs) that impedes the antimicrobial treatment of infections caused by Enterobacteriaceae in HIV patients and is a serious threat to the practice of modern medicine. Antimicrobial resistance in general, is a global health concern within the scientifi c community. Failure of recognizing antibiotic resistance in HIV/ AIDS patients can further complicate the overall therapeutic strategy of the containment of HIV and can also lead to a more compromised quality of life in HIV patients. In summary, antibiotic resistance poses a threat to everyone, but people living with HIV/AIDS are at more signifi cant risk.

Keynote Forum

Tariq M Rana

University of California San Diego, USA

Keynote: Targeting Vif regulatory Axis: developing new AIDS therapies
Conference Series STD-HIV AIDS 2019 International Conference Keynote Speaker Tariq M Rana photo

Tariq M Rana is a Scholar, Inventor, Entrepreneur and Multidisciplinary Scientist who is developing new therapies to treat infectious disease, cancer and immune disorders. He is a Professor and Chief of Genetics, V/C for Innovation in Therapeutics in the Department of Pediatrics at the University of California San Diego, School of Medicine, where his laboratory employs mechanisms and technologies of RNA, stem cells and chemical biology to discover new pathways implicated in human disease.


The human host is invaded by a wide range of microbial pathogens and has evolved a number of defensive mechanisms to survive these infections. In addition to adaptive immunity, it is becoming increasingly clear that innate immunity plays an important role in protecting host organisms from infections. One of the innate immune response mechanisms against viral infections involves a protein family, APOBEC3 (apolipoprotein B mRNA editing enzyme catalytic polypeptide 3). Th e APOBEC3 family of proteins can restrict replication of exogeneous retorviruses as well as Hepatitis B, a DNA virus that replicates through an RNA intermediate, and inhibit replication of retrotransposons. APOBEC3G (A3G) protein exhibits the most potent block to HIV-1 replication. To counteract host defense, HIV-1 expresses Vif protein that targets A3G for proteasomal degradation. Since HIV-1 Vif has no known cellular homologs, this protein represents an extremely attractive, yet unrealized, target for antiviral intervention. I will discuss the strategies to develop therapeutics that antagonize HIV-1 Vif function to inhibit HIV-1 replication. Further mechanistic investigation will be presented showing that Vif inhibitors’ function requires Vif-A3G interactions and restores A3G function. Th ese studies provide proof of principle that the HIV-1 Vif-A3G axis is a valid target for developing small molecule-based new therapies for AIDS or for enhancing innate immunity against viruses.

Conference Series STD-HIV AIDS 2019 International Conference Keynote Speaker Vsevolod A Zinserling photo

Vsevolod A Zinserling  is pathologist working in the fi eld of infectology in Saint-Petersburg, Russia. His research is devoted to  viral, bacterial, fungal and mycoplasma lesions of brain, lung, liver, intestine, placenta on autopsy, clinical and experimental material. Investigations of pathomorphology of Infl uenza, HIV and its complications, infections due to herpes viruses, viral hepatitis, mixed infections of different localisation are of special interest. Prof. V.A. Zinserling is collaborating at Saint-Petersburg University, Center of infectious pathology at S.P. Botkin hospital for infectious diseases and department of pathomorphology in the Institute of Experimental medicine at National Medical Research Center named after V.A. Almazov. He is active member of European Society of Pathology (working groups infectious diseases, autopsy pathology and history of pathology).  Author of more than 400 publications.


HIV infection remains one of the most dangerous diseases and important causes of death. Numerous investigations are devoted to problems of epidemiology, molecular biology, treatment, psychology etc. Th e number of studies discussing the results of pathological studies is very limited. Having long term experience in HIV pathology, we can formulate the following items. Most important questions to be studied on the autopsies of the deceased from HIV-infection: exact list of secondary infections and tumors with specifi cation of their localization; evaluation of the effi  cacy of treatment; revealing of immediate death cause; collection of specimen for further investigations in order to study the mechanisms of the disease and its complications. Methods recommended for postmortem investigation are detailed histological study of all macroscopically changed and not changed organs with use of certain special staining; bacteriological and mycological investigation of all suspected lesions in order to clarify their etiology and certain properties of the pathogens; diff erent virological, molecular-biological methods and immunohistochemistry in order to study the localization of lesions due to HIV and other viruses and some of their properties. Among the most interesting, important and not suffi  ciently known changes we pay special attention to the brain. We have to distinguish direct and indirect lesions due to HIV virus itself, other pathogens (CMV, Toxoplasma, Cryptococcus, HSV, JCV, EBV fi rst of all) and other infl uences and follow up them in diff erent decades of epidemics. Some clinico-pathological correlations in perinatal HIV: viral load in pregnant women correlated with the depth of immunosuppression; women without antiretroviral treatment had more expressed grade of immunosuppression; frequency of secondary purulent infl ammation correlated with the grade of immunosuppression. Main probable pathogenic mechanisms of Placenta lesion in HIV: direct lesions of placenta macrophages (Hofb auer cells), endotheliocytes and decidual cells with development of typical changes of nuclei, leading role in infl ammatory reaction of CD14+ in comparison with CD68+ cells; disturbance of angiogenesis due to hyper expression of anti-angiogenic factor TGFβ; probable disturbances of syncytial-capillary membrane. Main questions for further investigations: clarifying incidence and etiology of placenta infl ammation and intrauterine infections in women with HIV; further studies of mechanisms of placenta lesions in HIV infected women; clinico-pathological correlations between morphological changes in placenta and outcome of pregnancy versus antiretroviral treatment; Clinico-pathological correlations between symptoms in children from HIV-infected mothers and post-mortem histology; studying impact of prenatal infections on development of children and morbidity of teenagers and adults. Question for the life-time pathological and cytological diagnostics are study of smears or liquid biopsies of cerebrospinal fl uid for evaluating mycobacterium, cryptococci and tumour cells, lymph node biopsies in order to identify the origin of their lesion, needle biopsies of other organs due to clinical necessity